循环肿瘤DNA检测应用于非小细胞肺癌的研究进展

Research Progress in Application of Circulating Tumor DNA Detection in Non-small Cell Lung Cancer

肺癌是当今社会危害人类健康的一大疾病,肺癌的早期诊断、分子靶向治疗和监测肺癌的复发与转移对于提高肺癌患者的5年生存率尤为重要。目前临床尚未有任何一种检查和检测手段能够用于指导肺癌的全程治疗。近年来,随着液体活检技术的快速发展,循环肿瘤DNA(ctDNA)在非小细胞肺癌(NSCLC)的早期诊断、治疗和评估手术疗效及预后等方面取得了重要进展。ctDNA作为一个具有无创、可重复等优点的生物标志物在NSCLC的应用中体现出了巨大的临床应用价值。但其广泛应用于临床仍需进一步研究。

Lung cancer is a kind of disease that harms human health in today′s society.Therefore,early diagnosis, molecular targeted therapy and monitoring of lung cancer recurrence and metastasis are particularly important for improving the 5-year survival rate of the patients.At present,there is no clinical examination and detection method that can be used to guide the whole treatment of lung cancer.In recent years,with the rapid development of liquid biopsy technology,studies have reported significant progress of circulating tumor DNA(ctDNA) in the early diagnosis,treatment and evaluation of surgical efficacy and prognosis in non-small cell lung cancer(NSCLC).As a non-invasive,reproducible biomarker,ctDNA has shown great clinical value in the application of NSCLC.However,its wide application in clinical needs further study.